Stock Research: Takeda Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Takeda Pharmaceutical

TSE:4502 JP3463000004
32
  • Value
    8
  • Growth
    70
  • Safety
    Safety
    76
  • Combined
    60
  • Sentiment
    38
  • 360° View
    360° View
    32
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Takeda Pharmaceutical Co Ltd is a pharmaceutical company focused on research, development, and sale of pharmaceuticals. It focuses on gastrointestinal diseases, rare diseases, oncology, and neuroscience. The company operates in Japan, the United States, Europe, and China. In the last fiscal year, the company had a market cap of $46758 million, profits of $20016 million, and revenue of $30554 million, with 47455 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 32 (better than 32% compared with alternatives), overall professional sentiment and financial characteristics for the stock Takeda Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Takeda Pharmaceutical. The consolidated Value Rank has an attractive rank of 76, which means that the share price of Takeda Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 76% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 70, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 38. Professional investors are more confident in 62% other stocks. Worryingly, the company has risky financing, with a Safety rank of 8. This means 92% of comparable companies have a safer financing structure than Takeda Pharmaceutical. ...read more

more
Index
TOPIX 100
Nikkei 225
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
76 80 74 95
Growth
70 32 3 11
Safety
Safety
8 7 6 8
Sentiment
38 30 8 8
360° View
360° View
32 24 6 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
34 33 33 37
Opinions Change
50 83 24 50
Pro Holdings
n/a 24 14 32
Market Pulse
7 28 20 19
Sentiment
38 30 8 8
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
76 80 74 95
Growth
70 32 3 11
Safety Safety
8 7 6 8
Combined
60 18 6 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
34 26 30 71
Price vs. Earnings (P/E)
60 72 64 76
Price vs. Book (P/B)
73 83 73 87
Dividend Yield
93 93 98 96
Value
76 80 74 95
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
14 8 15 11
Profit Growth
83 23 6 14
Capital Growth
51 68 21 37
Stock Returns
84 60 49 65
Growth
70 32 3 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
17 14 7 4
Refinancing
4 19 11 25
Liquidity
28 16 22 18
Safety Safety
8 7 6 8

Similar Stocks

Discover high‑ranked alternatives to Takeda Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Megmilk Snow Brand

TSE:2270
Country: Japan
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Tokuyama

TSE:4043
Country: Japan
Industry: Specialty Chemicals
Size: Medium
Full Stock Analysis

Daicel

TSE:4202
Country: Japan
Industry: Diversified Chemicals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.